SMIM10L2A

Across TCGA pan-cancer cohorts, SMIM10L2A RNA differs between tumor and matched normal tissue in 12 of 18 cancer types tested, making tumor–normal expression one of SMIM10L2A’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where SMIM10L2A RNA is more highly expressed in tumor relative to normal tissue. In most cancer types SMIM10L2A is over-expressed in tumor, although a few such as STAD and BRCA show the opposite, repressed pattern.

THCA, STAD, and BRCA are the cancer types where SMIM10L2A tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SMIM10L2A RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	Female	II,III,IV	+1.499	<.001	7	view →
STAD	All	All	−0.669	<.001	7	view →
BRCA	Female	All	−1.931	<.001	6	view →
LUSC	Male	All	−0.856	<.001	6	view →
HNSC	Female	IV	−1.206	.002	4	view →
BLCA	All	IV	−1.015	.001	4	view →
CHOL	All	All	+1.155	<.001	3	view →
COAD	All	II,III,IV	−0.250	.011	3	view →
PRAD	All	All	−0.660	<.001	2	view →
KIRC	Female	All	+0.557	.006	2	view →
LUAD	All	All	−0.398	.020	2	view →
KIRC	Male	II,III,IV	−0.325	.015	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 12 lineages.

SMIM10L2A–THCA

Open the THCA breakdown →